Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis COVID-19 (FIBRO-COVID)

Phase-II Randomized Clinical Trial to Evaluate the Effect of Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis

Study population: Patients with fibrotic lung sequelae after recovery from acute phase of severe COVID19 pneumonia Objectives: To evaluate the effect of pirfenidone administered for 24 weeks in patients who have pulmonary fibrotic changes after suffering severe COVID19 pneumonia, analysed by

• % change in forced vital capacity (FVC)
• % fibrosis in high resolution computed tomography (HRCT) of the lung

Study Overview

• Status: Recruiting
• Conditions: Fibrotic Pulmonary Sequelae Post-COVID19 Infection
• Intervention / Treatment: Drug: Placebo; Drug: Pirfenidone

Detailed Description

Has been designed a clinical trial with an experimental and a control arm, with 2 experimental subjects per control (2:1), we will have to study 98 experimental subjects and 50 control subjects, in total 148 patients. Randomization will be performed using a centralized electronic system (IVRS) with 2: 1 randomized concealed assignment. This randomization will be done by permuted blocks.

The study population will be patients with fibrosing lung sequelae after recovery from severe COVID19 pneumonia.

This is a double-blind, masked, placebo-controlled clinical trial: the patient and the investigator are unaware of the assigned treatment the patient receives.

Patients will follow a total of 5 clinic visits; V0 (screening, -1 days - +42 days from signing the Informed Consent), V1 (randomization), V2 (week 12), V3 (week 24 or end of treatment), V4 (week 28 or follow-up).

Visits Plan

• V0 - Screening: Initially, the informed consent will be collected. Subsequently, we will proceed to collect clinical variables, blood tests and radiological characteristics (chest CT scan; radiological signs of fibrosis such as tractional bronchiolectasis, honeycombing, loss of lung volume and reticulation).
• V1 - Randomization: Before starting the drug:

Control analytics Serum pregnancy test for all women of childbearing age KBILD quality of life test. This validated questionnaire will be completed by the patient following the instructions of the staff.

Spirometry (CVF) and plethysmography (DLCO) TM6m. Extraction of blood for DNA isolation (in those cases that have specifically signed the IC for genetics) and proteins (serum).

Once the screening evaluation has been completed, eligibility will depend on meeting the inclusion criteria and not presenting any exclusion criteria. Those cases that are not eligible will be informed and an adequate explanation will be provided.

• V2 - 12 weeks after starting medication. The patient's clinical status will be collected
• V3 - 24 weeks (end of treatment period). Clinical data and quality of life test (KBILD) will be collected, and chest CT scan, spirometry-plethysmography and TM6m will be performed. Blood will be drawn for protein isolation (serum).
• V4 - 28 weeks (follow-up). Clinical and analytical variables will be collected.

Patients will have the telephone number of the main researcher or someone from the team where they can call 24 hours, which will be specified on the patient's card (where it will be identified that the patient participates in this study). In case of presenting any problem or side effect in the period between visits, the patient will go to the center and an additional visit will be made.

Study treatment:

Pirfenidone Name: Esbriet 267 mg hard capsules Dosage: 267 mg (capsules) Manufacturer: Roche Pharma AG

Study drug administration schedule: The study medication will be started at incremental doses, starting with 1602 mg / day (divided into three doses every 8 hours, 267 mg capsules with each meal) and, if there is no liver or associated serious events, will be increased on the 7th day to full doses of 2403 mg / day. The dose increase can be extended for one more week if the investigator considers it safer (slight elevation of liver enzymes, digestive discomfort or clear anorexia). Subsequently, 2403 mg / day will be maintained (3 capsules in each meal during the day) except if it is necessary to reduce the dose or suspend the drug due to adverse effects or associated problems (at the discretion of the researcher).

Concomitant treatments prohibited:

The use of the following therapies is prohibited during study treatment:

• Cytotoxic, immunosuppressant, cytokine modulators, including but not limited to azathioprine, bosentan, ambrisentan, cyclophosphamide, cyclosporine, etanercept, iloprost, infliximab, leukotriene antagonists, methotrexate, high doses of corticosteroids (more than 15 mg / day of prednisone or equivalent for more than 20 days), mycophenolate mofetil, tacrolimus, montelukast, tetrathiomolybdate, TNF-α inhibitors, imatinib mesylate, interferon gamma-1b, and tyrosine kinase inhibitors.
• Strong CYP1A2 inhibitors (eg, Fluvoxamine, Enoxacin), P-glycoprotein inhibitors (eg, Ketoconazole, erythromycin) or CYP3A4 (eg, Ketoconazole, erythromycin), or their inducers (eg. Eg, rifampicin, carbamazepine, phenytoin).
• Any investigational therapy in an active clinical trial.
• Because moderate CYP1A2 inhibitors (eg, Ciprofloxacin) increase the systemic exposure of pirfenidone (Esbriet® US label 2014), if ciprofloxacin is administered, it should be limited to 250 or 500 mg daily (QD), and the patient should be closely monitored.

Prohibited foods: The consumption of grapefruit juice will be prohibited during the study.

Additional restriction: The use of any form of tobacco consumption will be prohibited.

Criteria for patient withdrawal from the study Participation in the study is voluntary and the subjects can withdraw at any time without having to give explanations and without this implying a detriment to the healthcare they receive in the future.

For her part, the researcher must withdraw a subject from the study:

• Adverse event or clinical situation of the patient that, in the clinical opinion, makes it necessary to withdraw from the study. Patients can interrupt the medication for up to 14 days, returning to the previous dose without requiring titration. If they interrupt for more than 14 days, they have to gradually increase the dose. If the patient cannot tolerate the minimum dose, then the treatment will be withdrawn, allowing study visits to be completed.
• Request for withdrawal by the patient.
• Serious violation of protocol.
• Loss of follow-up.
• Pregnancy during the study. When a subject withdraws from the study, the investigator will record the reason or reasons for withdrawal in the original documents in the Medical Record.

End of clinical trial is defined as the date the last recruited patient completes the last visit (LPLV). The last patient is expected to complete the last visit 4 weeks after the last patient has completed treatment, which is expected to happen 14 months after the start of the study.

• Study Type: Interventional
• Enrollment (Anticipated): 148
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Guadalupe Bermudo, MD, PhD; Phone Number: 00342607689; Email: ufip@bellvitgehospital.cat

Study Locations

• Spain
  • Badalona, Spain
    • Active, not recruiting
    • Hospital Germans Trias i Pujol
  • Barcelona, Spain
    • Not yet recruiting
    • Hospital Sant Pau
    • Contact: Diego Castillo, PI
  • Barcelona, Spain
    • Active, not recruiting
    • Hospital Clinic
  • Barcelona, Spain
    • Active, not recruiting
    • Hospital Del Mar
  • Madrid, Spain
    • Active, not recruiting
    • Hospital La Princes
  • Madrid, Spain
    • Not yet recruiting
    • Hospital Ramón y Cajal
    • Contact: David Jimenez, MD, PhD
  • Madrid, Spain
    • Not yet recruiting
    • Hospital Puerta de Hierro
    • Contact: Piedad Usetti, MD, PhD
  • Barcelona
    • Hospitalet de Llobregat, Barcelona, Spain, 08907
      • Recruiting
      • University Hospital of Bellvitge
      • Contact: Guadalupe Bermudo, PI; Phone Number: 0034 932607689; Email: lupebermudope@gmail.com
      • Principal Investigator: Claudia Valenzuela, PI
      • Principal Investigator: Rosalia Laporta, PI
      • Principal Investigator: Juan Rigual, PI
      • Principal Investigator: Diego Castillo, PI
      • Principal Investigator: Jacobo Sellarés, PI
      • Principal Investigator: Karina Portillo, PI
      • Principal Investigator: Eva Balcells, PI

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Age > 18 years
• Signed Informed Consent Form
• Ability to comply with the study protocol in the opinion of the Investigator
• Confirmation of SARS-COV2 infection in previous weeks (Confirmation of negativity or no activity of SARS-COV2 before randomization using the usual tests performed in the hospital), which induced severe pneumonia and ARDS, with subsequent torpid recovery and/or incipient clinical-radiological signs of pulmonary fibrosis.
• HRCT with fibrotic radiological changes of at least 5% after recovery from the acute process (HRCT chest during the screening period, performed minimum after 1 month of the acute phase and maximum 90 days after hospital discharge)
• Be able to understand the information given and sign the informed consent
• For women or men of childbearing age who are not sterile, a commitment to use non-hormonal contraception during the 24-week treatment period will be required.

Exclusion Criteria:

• Use of systemic steroids (oral or intravenous) at doses greater than 15 mg/day one month prior to randomisation.
• Severe or moderate myopathy that may associate a decrease of FVC.
• Severe or life-limiting chronic disease prior to COVID19 infection, including severe asthma, cancer, clinical dementia, IPF, or uncontrolled ischemic cardiomyopathy.
• Treatment with pirfenidone or nintedanib prior to Covid19
• Concomitant treatment with significant interactions with pirfenidone (such as fluvoxamine).
• Participation in any other investigational trial throughout the study
• Active smoking.

• Relevant blood alterations in the analysis made during the screening period:

  • Total bilirubin > 2 ULN
  • AST/SGOT or ALT/SGPT > 2.5 ULN
  • Alkaline phosphatase >3.0 ULN
  • Creatinine Clearance <40 mL/min, calculated by the Cockcroft-Gault formula
• Pregnancy or lactation
• Concomitant treatments that can cause severe digestive problems.
• Gastric surgery in the last 3 months or similar procedures that may increase gastric intolerance.
• Inability to complete required visits.
• Previous intolerance or allergy to pirfenidone or hypersensitivity to any of its excipients.
• History of angioedema

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo; No anti-fibrotic treatment. Patients in placebo and treatment arm may be on corticosteroid treatment	Drug: Placebo; Comparing the effect of pirfenidone in avoiding establishing or progression of fibrosis induced after COVID19 infection
Experimental: Treatment; Pirfenidone	Drug: Pirfenidone; Comparing the effect of pirfenidone in avoiding establishing or progression of fibrosis induced after COVID19 infection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To investigate the effect of pirfenidone on fibrotic signs induced by COVID19 infection	To investigate the effect of pirfenidone administered for 24 weeks measuring the number of patients who have pulmonary fibrotic changes from baseline after suffering severe COVID19 pneumonia, analysed by; Change From Baseline in % in forced vital capacity (FVC); Change From Baseline % fibrosis in high resolution computed tomography (HRCT) of the lung	24 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maintenance of stability or functional improvement FVC	Number of patients who show maintenance of stability or functional improvement: stability will be considered when the FVC does not increase more than 10% or does not decrease more than 10% and the DLCO does not increase more than 15% or decreases more than 15%. An increase in% FVC greater than 10% or in DLCO greater than 15% will be considered significant improvement.	24 weeks
Decreased oxygen requirement for physical activity	Rate of decreased oxygen requirement for physical activity in patients	24 weeks
Improved exercise capacity (> 50 meter improvement or less decrease in% oxygen saturation) in the TM6m	Number of patients who have improved exercise capacity (> 50 meter improvement or less decrease in% oxygen saturation) in the TM6m	24 weeks
Hospitalizations (general and due to respiratory problems)	Number of Hospitalizations (general and due to respiratory problems)	24 weeks
Visits to the Emergency or Day Hospital for respiratory causes	Number of Visits to the Emergency or Day Hospital for respiratory causes	24 weeks
Lung transplantation	Number of patients who need Lung transplantation	24 weeks
Death	Number of patients who die	24 weeks

Collaborators and Investigators

• Sponsor: Institut d'Investigació Biomèdica de Bellvitge
• Investigators: Study Chair: Maria Molina-Molina, MD, PhD, Institut d'Investigació Biomèdica de Bellvitge

Study record dates

Study Major Dates

• Study Start (Actual): August 1, 2020
• Primary Completion (Anticipated): January 30, 2022
• Study Completion (Anticipated): June 30, 2022

Study Registration Dates

• First Submitted: October 28, 2020
• First Submitted That Met QC Criteria: October 28, 2020
• First Posted (Actual): October 29, 2020

Study Record Updates

• Last Update Posted (Actual): December 30, 2021
• Last Update Submitted That Met QC Criteria: December 29, 2021
• Last Verified: December 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19; Pulmonary Fibrosis; Physiological Effects of Drugs; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Antineoplastic Agents; Pirfenidone
• Other Study ID Numbers: 2020-002518-42

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No